Evidence-based treatment of anxiety disorders

References

• Sackett DL, Rosenberg WMC, Gray MJA, et al. Evidence-based medicine: what it is and what it isn't. Br Med J 1996; 312: 71–2
   PubMed Web of Science ®Google Scholar
• Evidence-Based Medicine Working Group. Evidence-based medicine. J Am Med Assoc 1992.268:2420–25.
   PubMed Web of Science ®Google Scholar
• MJ Field, Lohr, KN, editors. 1992. Guidelines for clinical practice. From development to use. Washington, DC: National Academy Press.
   Google Scholar
• Timmermans S, Kolker ES. Evidence-based medicine and the reconfiguration of medical knowledge. J Health Soc Behav 2004; 45(Suppl 1)177–93
   Google Scholar
• Bauchner H, Simpson L. Specific issues relating to developing, disseminating, and implementing pediatric practice guidelines for physicians, patients, families, and other stakeholders. Health Serv Res 1998; 33: 1161–77
   Google Scholar
• Klein DF. Clinical psychopharmacologic practice. The need for developing a research base. Arch Gen Psychiatry 1993; 50: 491–4
   PubMed Web of Science ®Google Scholar
• Jackson R, Feder G. Guidelines for clinical guidelines. Br Med J 1998; 317: 427–8
   PubMedGoogle Scholar
• Lam RW, Kennedy SH. Using meta-analysis to evaluate evidence: practical tips and traps. Can J Psychiatry 2005; 50: 167–74
   PubMed Web of Science ®Google Scholar
• Doherty S. Evidence-based medicine: arguments for and against. Emerg Med Australia 2005; 17: 307–13
   Google Scholar
• Klein DF. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 2000; 157: 1204–11
   PubMed Web of Science ®Google Scholar
• Stern M, Brennan S. Medical audit in the hospital and community health services. Department of Health, London 1994
   Google Scholar
• Practice Guideline for the Treatment of Patients with Panic Disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry 1998;155((Suppl 5)):1–34.
   Google Scholar
• Bernstein GA, Shaw K. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36(Suppl 10)69–84S
   Google Scholar
• American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998;37((Suppl 10)):27–45S.
   Google Scholar
• American Academy of Child and Adolescent Psychiatry. Practice Parameters for the assessment and treatment of children and adolescents with Posttraumatic Stress Disorder. J Am Acad Child Adolesc Psychiatry 1998;37((Suppl 10)):4–26S.
   Google Scholar
• March, JS, Frances, A, Kahn, DA, Carpenter, D, editors. The Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58((Suppl 4)).
   Google Scholar
• Foa, EB, Davidson, JRT, Frances, A, editors. The Expert Consensus Guideline Series: Treatment of Posttraumatic Stress Disorder. J Clin Psychiatry 1999;60((Suppl 16)).
   Google Scholar
• Allgulander C, Bandelow B, Hollander E, et al. World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003; 8(Suppl 1)53–61
   PubMed Web of Science ®Google Scholar
• Stein DJ, Bandelow B, Hollander E, et al. World Council of Anxiety. WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr 2003; 8(Suppl 1)31–9
   Google Scholar
• Pollack MH, Allgulander C, Bandelow B, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 2003; 8(Suppl 1)17–30
   Google Scholar
• NICE Clinical Guideline 22. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Issue date:, December 2004 ( www.nice.org.uk/CG022NICEguideline).
   Google Scholar
• NICE Clinical Guideline 26. Post-traumatic stress disorder (PTSD): The management of PTSD in adults and children in primary and secondary care. Issue date:, March 2005 ( www.nice.org.uk/CG026NICEguideline).
   Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62(Suppl 11)53–8
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. WFSBP Task Force on Treatment Guidelines for Anxiety, O.-C. a P.S.D., 2002. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171–99
   PubMedGoogle Scholar
• Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; 2: CD003592
   Google Scholar
• Schmitt R, Gazalle FK, Lima MS, et al. The efficacy of antidepressants for generalized anxiety disorder: A systematic review and meta-analysis. Rev Bras Psiquiatr 2005; 27: 18–24
   PubMedGoogle Scholar
• Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63(Suppl 14)9–16
   PubMedGoogle Scholar
• Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002; 63(Suppl 8)17–23
   Google Scholar
• Davidson RT. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl 11)46–50
   PubMedGoogle Scholar
• Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioural and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behav Res Ther 1997; 28: 285–305
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Wittchen HU, Fehm L. Epidemiology, patterns of comorbidity and associated disabilities in social disorders. Psychiatr Clin North Am 2001; 72: 71–9
   Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Barnett SD, Davidson JRT. Social anxiety disorder in review: Two decades of progress. Int J Neuropsychopharmacol 2001; 4: 279–98
   Google Scholar
• Narrow WE, Rae DS, Robins LR, Regier DA. Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys estimates. Arch Gen Psychiatr 2002; 59: 115–23
   PubMed Web of Science ®Google Scholar
• Davidson JR, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: Findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993; 23: 709–18
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JA, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatr 1998; 59: 54–60
   PubMed Web of Science ®Google Scholar
• Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: Current treatment recommendations. CNS Drugs 2005; 19: 377–91
   PubMedGoogle Scholar
• Davidson JR. Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl 2003; 417: 65–71
   Google Scholar
• Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: A meta-analysis. Depress Anxiety 2003; 18: 29–40
   PubMed Web of Science ®Google Scholar
• van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15(Suppl 2)S15–23
   PubMedGoogle Scholar
• Stein DJ, Stahl S. Serotonin and anxiety: Current models. Int Clin Psychopharmacol 2000; 15(Suppl 2)S1–6
   PubMedGoogle Scholar
• Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004; 4: CD001206
   Google Scholar
• Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000; 20(6)636–44
   Google Scholar
• Van Ameringen M, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatr 2001; 158: 275–81
   PubMed Web of Science ®Google Scholar
• Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Arch Gen Psychiatr 2002; 59: 111–18
   Google Scholar
• Van Ameringen M, Mancini C, Patterson B, Bennett M. An evaluation of paroxetine in generalised social anxiety disorder. Expert Opin Pharmacother 2005; 6(5)819–30
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology 2004; 174: 163–76
   PubMed Web of Science ®Google Scholar
• Auquier P, Robitail S, Llorca P-M, et al. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatr Clin Pract 2003; 7: 259–68
   PubMed Web of Science ®Google Scholar
• Baldwin, DS, Huusom, AKT, Mæhlum, E. A Randomised placebo-controlled trial of escitalopram and paroxetine in the treatment of generalised anxiety disorder. Presented at the 17th College of Neuropsychopharmacology, Stockholm, Sweden. October 9–11, 2004.
   Google Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24- week treatment of social anxiety disorder: Randomized, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241–8
   PubMed Web of Science ®Google Scholar
• Montgomery, SA, Lader, M, Bürger, V, et al. Escitalopram and raroxetine in fixed doses for the treatment of social anxiety disorder (SAD). Poster presented at the 44th Annual Meeting of the Scandinavian College of Neuro-psychopharmacology, April 2003, Juan-les-Pins, France.
   Google Scholar
• Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998; 18(5)373–8
   Google Scholar
• Montgomery SA, Nil R, Dürr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–8
   PubMed Web of Science ®Google Scholar
• Brunello N, den Boer JA, Judd LL, et al. Social phobia: Diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord 2000; 60: 61–74
   PubMed Web of Science ®Google Scholar